Literature DB >> 17727455

Helicobacter pylori inflammation, immunity, and vaccines.

Mario Milco D'Elios1, Leif P Andersen.   

Abstract

Helicobacter pylori infects almost 50% of the world population and is the major cause of gastroduodenal diseases. H. pylori colonizes the gastric mucosa, activates Toll-like and Nod-like receptors, and usually elicits a T helper 1 (Th1) type of immune response, fully polarized in peptic ulcer patients. Among several bacterial factors, the neutrophil-activating protein represents a key factor driving Th1 inflammation. A complex and fascinating balance between H. pylori and host factors takes part in the gastric niche and allows the majority of infected individuals to be without any symptom during their entire life. Novel insights into the innate and adaptive responses against H. pylori, dealing with regulatory T cells and cytokines, CTLA-4 molecule, cholesterol glucosylation, and immune evasion have been elucidated during the past year and are discussed for the development of an effective vaccine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17727455     DOI: 10.1111/j.1523-5378.2007.00530.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  12 in total

1.  The significance of E266K polymorphism in the NOD1 gene on Helicobacter pylori infection: an effective force on pathogenesis?

Authors:  Banu Kara; Hikmet Akkiz; Figen Doran; Suleyman Bayram; Eren Erken; Yuksel Gumurdullu; Macit Sandikci
Journal:  Clin Exp Med       Date:  2009-10-31       Impact factor: 3.984

Review 2.  Use of probiotics in the fight against Helicobacter pylori.

Authors:  Paolo Ruggiero
Journal:  World J Gastrointest Pathophysiol       Date:  2014-11-15

3.  Development of monoclonal antibody-based immunoassays for detection of Helicobacter pylori neutrophil-activating protein.

Authors:  Ianko D Iankov; Alan R Penheiter; Stephanie K Carlson; Evanthia Galanis
Journal:  J Immunol Methods       Date:  2012-06-28       Impact factor: 2.303

4.  Essential role for macrophage migration inhibitory factor in gastritis induced by Helicobacter pylori.

Authors:  Benny L W Wong; Sen-Lin Zhu; Xiao R Huang; Juan Ma; Harry H X Xia; Richard Bucala; Benjamin C Y Wong; Hui Yao Lan
Journal:  Am J Pathol       Date:  2009-03-12       Impact factor: 4.307

5.  Chronic gastritis and bone mineral density in women.

Authors:  Adriana M Kakehasi; Carolinne B Rodrigues; Ariane V Carvalho; Alfredo J A Barbosa
Journal:  Dig Dis Sci       Date:  2008-08-07       Impact factor: 3.199

6.  Helicobacter pylori: bacterial factors and the role of cytokines in the immune response.

Authors:  Tania Beatriz Romero-Adrián; Jorymar Leal-Montiel; Francisca Monsalve-Castillo; Edgardo Mengual-Moreno; Ernesto García McGregor; Lenis Perini; Ana Antúnez
Journal:  Curr Microbiol       Date:  2009-10-22       Impact factor: 2.188

Review 7.  Oral medications for central serous chorioretinopathy: a literature review.

Authors:  William Fusi-Rubiano; Habiba Saedon; Vijay Patel; Yit C Yang
Journal:  Eye (Lond)       Date:  2019-09-16       Impact factor: 3.775

8.  Helicobacter pylori as a potential target for the treatment of central serous chorioretinopathy.

Authors:  Antonio Marcelo Barbante Casella; Rodrigo Fabri Berbel; Gláucio Luciano Bressanim; Marcus Rudolph Malaguido; José Augusto Cardillo
Journal:  Clinics (Sao Paulo)       Date:  2012-09       Impact factor: 2.365

9.  Case-control study of association of eosinophilic gastrointestinal disorders with Helicobacter pylori infection in Japan.

Authors:  Kenji Furuta; Kyoichi Adachi; Masahito Aimi; Norihisa Ishimura; Shuichi Sato; Shunji Ishihara; Yoshikazu Kinoshita
Journal:  J Clin Biochem Nutr       Date:  2013-04-19       Impact factor: 3.114

10.  Genetic polymorphisms and tissue expression of interleukin-22 associated with risk and therapeutic response of gastric mucosa-associated lymphoid tissue lymphoma.

Authors:  F Liao; Y-C Hsu; S-H Kuo; Y-C Yang; J-P Chen; P-N Hsu; C-W Lin; L-T Chen; A-L Cheng; C S J Fann; J-T Lin; M-S Wu
Journal:  Blood Cancer J       Date:  2014-10-10       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.